MicroVision, Inc. Files Q2 2024 10-Q Report

Ticker: MVIS · Form: 10-Q · Filed: 2024-08-08T00:00:00.000Z

Sentiment: neutral

Topics: 10-Q, financials, reporting

TL;DR

MicroVision's Q2 10-Q is in. Check financials.

AI Summary

MicroVision, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results for the second quarter and the first half of the year. Specific financial figures and operational details are provided within the filing.

Why It Matters

This filing provides investors and stakeholders with the latest financial performance and operational status of MicroVision, Inc., crucial for understanding the company's current health and future prospects.

Risk Assessment

Risk Level: medium — As a technology company, MicroVision faces inherent risks related to product development, market adoption, and competition, which are detailed in their SEC filings.

Key Numbers

Key Players & Entities

FAQ

What is the reporting period for this 10-Q filing?

The 10-Q filing reports on the period ending June 30, 2024.

When was this 10-Q filed with the SEC?

This 10-Q was filed on August 8, 2024.

What is MicroVision, Inc.'s fiscal year end?

MicroVision, Inc.'s fiscal year ends on December 31.

What is the company's primary business address?

The company's business address is 18390 NE 68TH STREET, REDMOND, WA 98052.

What is the SEC file number for MicroVision, Inc.?

The SEC file number for MicroVision, Inc. is 001-34170.

Filing Stats: 4,627 words · 19 min read · ~15 pages · Grade level 15.2 · Accepted 2024-08-07 20:20:35

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited) 3 Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 3 Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023 4 Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2024 and 2023 5 Condensed Consolidated Statements of Shareholders' Equity for the three and six months ended June 30, 2024 and 2023 6 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 7 Notes to Condensed Consolidated Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 21

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 25

Controls and Procedures

Item 4. Controls and Procedures 26

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 26

Risk Factors

Item 1A. Risk Factors 26

Other Information

Item 5. Other Information 34

Exhibits

Item 6. Exhibits 35

Signatures

Signatures 36 2 PART I. ITEM 1. FINANCIAL STATEMENTS MicroVision, Inc. Condensed Consolidated Balance Sheets (In thousands, except per share data) (Unaudited) June 30, December 31, 2024 2023 Assets Current assets Cash and cash equivalents $ 26,748 $ 45,167 Investment securities, available-for-sale 29,934 28,611 Restricted cash, current 73 3,263 Accounts receivable, net of allowances 1,970 949 Inventory 4,203 3,874 Other current assets 3,646 4,890 Total current assets 66,574 86,754 Property and equipment, net 8,131 9,032 Operating lease right-of-use assets 12,348 13,758 Restricted cash, net of current portion 1,961 961 Intangible assets, net 13,081 17,235 Other assets 1,321 1,895 Total assets $ 103,416 $ 129,635 Liabilities and shareholders' equity Current liabilities Accounts payable $ 1,448 $ 2,271 Accrued liabilities 8,894 8,640 Accrued liability for Ibeo business combination - 6,300 Contract liabilities 172 300 Operating lease liabilities, current 2,113 2,323 Other current liabilities 24 669 Total current liabilities 12,651 20,503 Operating lease liabilities, net of current portion 11,936 12,714 Other long-term liabilities 120 614 Total liabilities 24,707 33,831 Commitments and contingencies - - Shareholders' equity Preferred stock, par value $ 0.001 ; 25,000 shares authorized; zero and zero shares issued and outstanding as of June 30, 2024 and December 31, 2023 - - Common stock, par value $ 0.001 ; 310,000 shares authorized; 211,961 and 194,736 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 212 195 Additional paid-in capital 894,005 860,765 Accumulated other comprehensive income 101 210 Accumulated deficit ( 815,609 ) ( 765,366 ) Total shareholders' equity 78,709 95,804 Total liabilities and shareholders' equity $ 103,416 $ 129,635 The accompanying notes are an integral

View on Read The Filing